MedPath

Angiogenic Biomarkers in Juvenile Idiopathic Arthritis

Recruiting
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
Biological: Blood sample
Biological: Joint puncture
Registration Number
NCT05534347
Lead Sponsor
Assistance Publique - HĂ´pitaux de Paris
Brief Summary

The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.

Detailed Description

Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic inflammatory rheumatic diseases beginning before the age of 16. The most common pediatric rheumatologic disease. JIA is the most common pediatric rheumatologic disease. Apart from clinical features and the biological inflammatory syndrome, no predictive parameter for the severity of JIA, especially polyarticular JIA, has been identified. The team has been interested in the prognosis of RA for many years. Thus, the investigators have conducted various studies in search of biological parameters associated with the joint prognosis of RA patients, which allowed the investigator to discover the interest of angiogenic and inflammatory biomarkers such as semaphorins and CCN1 protein. This has been demonstrated in vitro but also in vivo from sera of RA patients. These markers are associated with activity and structural damage in RA.

The project aims to study the interest of these same angiogenic biomarkers in the serum of JIA patients in order to establish whether, as in RA, they are also associated with disease severity.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Greater than or equal to 16 years-old
  • Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital
  • No-opposition to the research
  • Patient with health insurance
  • Mastery of the French language
Exclusion Criteria
  • Patient under curatorship or guardianship
  • Patient receiving french state medical aid

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Juvenile Idiopathic ArthritisBlood samplePatients seen in a specialized rheumatology consultation for the management of juvenile idiopathic arthritis in an adult service, after information and collection of their non-opposition.
Juvenile Idiopathic ArthritisJoint puncturePatients seen in a specialized rheumatology consultation for the management of juvenile idiopathic arthritis in an adult service, after information and collection of their non-opposition.
Primary Outcome Measures
NameTimeMethod
Dosage of angiogenic markers5 years

Dosage of angiogenic markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received.

Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

Dosage of inflammatory markers by ELISA method5 years

Dosage of inflammatory markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received.

Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

Secondary Outcome Measures
NameTimeMethod
Collection of treatments received5 years

Severity of JIA

Inflammatory biomarkersAt inclusion

Determine if sera inflammatory biomarkers are associated with clinical subtypes of JIA.

Questionnaires5 years

Severity of JIA

Angiogenic biomarkersAt inclusion

Determine if sera angiogenic biomarkers are associated with clinical subtypes of JIA.

Structural damage determined by x-rays5 years

Structural damage determined by x-rays during follow up.

Trial Locations

Locations (1)

Rheumatology Department, Cochin Hospital

🇫🇷

Paris, IDF, France

© Copyright 2025. All Rights Reserved by MedPath